We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Differential hRad17 expression by histologic subtype of ovarian cancer.
- Authors
Young, Jennifer L.; Koon, E. Colin; Kwong, Joseph; Welch, William R.; Muto, Michael G.; Berkowitz, Ross S.; Mok, Samuel C.
- Abstract
Background: In the search for unique ovarian cancer biomarkers, ovarian specific cDNA microarray analysis identified hRad17, a cell cycle checkpoint protein, as over-expressed in ovarian cancer. The aim of this study was to validate this expression. Methods: Immunohistochemistry was performed on 72 serous, 19 endometrioid, 10 clear cell, and 6 mucinous ovarian cancers, 9 benign ovarian tumors, and 6 normal ovarian tissue sections using an anti-hRad17 antibody. Western blot analysis and quantitative PCR were performed using cell lysates and total RNA prepared from 17 ovarian cancer cell lines and 6 normal ovarian epithelial cell cultures (HOSE). Results: Antibody staining confirmed upregulation of hRad17 in 49.5% of ovarian cancer cases. Immunohistochemistry demonstrated that only 42% of serous and 47% of endometrioid subtypes showed overexpression compared to 80% of clear cell and 100% of mucinous cancers. Western blot confirmed overexpression of hRad17 in cancer cell lines compared to HOSE. Quantitative PCR demonstrated an upregulation of hRad17 RNA by 1.5-7 fold. hRad17 RNA expression differed by subtype. Conclusions: hRad17 is over-expressed in ovarian cancer. This over-expression varies by subtype suggesting a role in the pathogenesis of these types. Functional studies are needed to determine the potential role of this protein in ovarian cancer.
- Subjects
OVARIAN cancer; BIOMARKERS; DNA microarrays; PROTEINS; IMMUNOHISTOCHEMISTRY
- Publication
Journal of Ovarian Research, 2011, Vol 4, Issue 1, p1
- ISSN
1757-2215
- Publication type
Article
- DOI
10.1186/1757-2215-4-6